From GlobeNewswire: 2025-03-19 07:00:00

HUTCHMED reports financial results for 2024, including total oncology products in-market sales up 134% to $501.0 million, with a net income of $37.7 million and a cash balance of $836.1 million. Key clinical developments include positive results for various drug candidates in different phases of development, with ongoing global clinical trials and regulatory approvals.

The company achieved commercial success with FRUZAQLA® with in-market sales outside China reaching $290.6 million in 2024, triggering a sales milestone. Other products like ELUNATE® and SULANDA® also showed growth. Regulatory updates include multiple approvals and acceptances for different indications in various countries.

HUTCHMED’s late-stage clinical development activities focus on drug candidates like savolitinib, fruquintinib, sovleplenib, surufatinib, tazemetostat, and others, with positive results and ongoing trials in various indications. The company also introduced the Antibody-Targeted Therapy Conjugate (ATTC) platform for potential new drug candidates with improved efficacy and safety profiles.

In terms of sustainability, HUTCHMED is committed to embedding sustainability in its operations, with progress made in various areas like climate actions, biodiversity assessment, and supplier ESG assessment. The company received multiple ESG awards in 2024 for its sustainability efforts within the pharmaceutical industry.

Financially, HUTCHMED provided guidance for 2025 with a range of $350 million to $450 million for Oncology/Immunology consolidated revenue. The company’s balance sheet remains strong, supporting investments to bring innovative medicines to patients globally. The full financial report is available for further details on the company’s performance and outlook.



Read more at GlobeNewswire:: HUTCHMED Reports 2024 Full Year Results and Provides